A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
Clinical trial NCT03066778 · COMPLETED
Trial details
- NCT number
- NCT03066778
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-02
- Primary completion
- 2019-12-02
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.